A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 μg) of formoterol-hfa (pMDI) vs. those of a dose level (24 μg) of formoterol-DPI (Foradil®/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients: Formoterol Modulite® (Atimos®/Forair®): Tailoring Treatment to Patients' Needs

A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 μg) of formoterol-hfa (pMDI) vs. those of a dose level (24 μg) of formoterol-DPI (Foradil®/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients: Formoterol Modulite® (Atimos®/Forair®): Tailoring Treatment to Patients' Needs

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Respiration 2005, Vol.72, p.13-19
Hauptverfasser: BOUSQUET, J, GUENOLE, E, DUVAUCHELLE, T, VICAUT, E, LEFRANCOIS, G
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Chronic obstructive pulmonary disease, asthma
Medical sciences
Pneumology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:0025-7931
1423-0356